Showing 2531-2540 of 5771 results for "".
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- C. Light Technologies Announces Activities and New Partnerships at ARVOhttps://modernod.com/news/c-light-technologies-announces-activities-and-new-partnerships-at-arvo/2480821/At this year’s Association for Research in Vision and Ophthalmology (ARVO), C. Light Technologies will meet with colleagues at booth #2424 to share engineering and software development updates from their new pipeline instrument,
- American Academy of Optometry announces the 2022 ARVO Student Travel Fellowship Grant Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-the-2022-arvo-student-travel-fellowship-grant-recipients/2480811/
- Registration Now Open for Neuro-Optometric Rehabilitation Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-annual-conference/2480810/Registration is now open for the Neuro-Optometric Rehabilitatio
- Envision Invites Students Across the Country Who are Blind or Visually Impaired to Prepare for College and Careers with Annual Level Up Technology Camphttps://modernod.com/news/envision-invites-students-across-the-country-who-are-blind-or-visually-impaired-to-prepare-for-college-and-careers-with-annual-level-up-technology-camp/2480791/Envision has opened high school registration for the 2022 Level Up Technology Camp designed to equip students with vision loss with academic, professional and interpersonal skills needed for college and beyond. High school students with vision loss across the United States ar
- ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategyhttps://modernod.com/news/proqr-announces-additional-sepofarsen-illuminate-trial-analyses-and-provides-update-on-company-strategy/2480765/ProQR Therapeutics provided an update on its sepofarsen program following a comprehensive post-hoc analysis of the data from the phase 2/3 Illuminate trial in people with CEP290-mediated Lebercongenital amaurosis 10, or LCA10, a
- SightGlass Vision Announces Andrew Sedgwick as CEO, Names Additional Executive Leadershttps://modernod.com/news/sightglass-vision-announces-andrew-sedgwick-as-ceo-names-additional-executive-leaders/2480716/SightGlass Vision has named three eye care industry veterans to executive leadership positions. This follows the recent finalization of a joint venture operating agreement for the business between CooperCompanies and EssilorLuxottica. Andrew Sedgwick has been appointed as chief exe
- Innovega Announces Public Funding Campaign with StartEngine.comhttps://modernod.com/news/innovega-announces-public-funding-campaign-with-startenginecom/2480709/Innovega, a developer of next-generation display eyewear for augmented reality, virtual reality (AR/VR) and Metaverse applications, launched an online funding campaign with StartEngine, a equity crowdfunding platform. Innovega has raised more than $16 million in total funding,
- Nicox Announces Vyzulta Now Commercialized in 7 Territories and Approved in Further 9 Countrieshttps://modernod.com/news/nicox-announces-vyzulta-now-commercialized-in-7-territories-and-approved-in-further-9-countries/2480660/Nicox provided an update on the approvals and launches of Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%, exclusively licensed worldwide by Nicox to Bausch + Lomb. “Vyzulta is the first product based on our nitric oxide-donating research platform which has bee
- Oxurion Announces New Data on THR-149 Phase 2 KALAHARI Clinical Trial in DME at the Angiogenesis 2022 Conferencehttps://modernod.com/news/oxurion-announces-new-data-on-thr-149-phase-2-kalahari-clinical-trial-in-dme-at-the-angiogenesis-2022-conference/2480637/